Different members of the MCM complex (MCM2 and MCM4) have previously been identified as markers of proliferation, associated with poorer survival outcomes in breast cancer and shown to have higher expression in ER-negative breast tumors (Joshi et al., 2015, Kwok et al., 2015). This evidence concerns the gene MCM2 and breast carcinoma.